Insider buying last 90 days
No open-market insider purchases were filed for SLS in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every SLS insider filing, plotted on the chart in Gekko.Open SLS in Gekko
NASDAQ: SLS
SELLAS Life Sciences (SLS) Stock Analysis & Forecast
Oct 12 close
$11.93+0.28 (+2.4%)
Gekko Brief
AI summaryOct 12 closeThis week's attention on SELLAS Life Sciences (SLS) centers on a securities fraud investigation by Pomerantz Law Firm, concerning the company's phase 3 clinical trial for Galinpepimut-S (GPS), following reports that the trial reached a pre-specified event, the 80th patient death. Separately, an options chain update noted a lack of available call or put options for November 2026.
SLS closed at $11.93, up 2.4%, with its close sitting between the 50-day average of $12.44 and the 200-day average of $8.05, reflecting a mixed trend picture. The GekkoIndex reads 58.5, placing the stock in the Neutral zone, down 1.8 over five sessions. Shares trade 32.2% below Gekko Fair Value of $17.59.
Looking ahead, the next earnings report is scheduled for 11 November 2026, 29 days out, which falls outside a typical 20-trading-day holding window; the prior report on 11 August showed an EPS of -0.05 against a -0.04 estimate, with a 6.6% reaction, and the company has beaten estimates in 7 of the last 8 quarters. No insider, Congress or unusual options activity appears in the current windows. Seasonally, the next 20 trading days have averaged a 28.2% return over 5 years, though gains occurred in only 2 of those years. Consensus analyst targets stand at $32.5, implying 172.4% upside.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
SELLAS Life Sciences price vs fair value
Close $11.93200-day averageGekko Fair Value $17.59
SELLAS Life Sciences quick facts
- Market cap
- $2.22B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$0.21
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 2.57
- Volume
- 4.02M avg 5.18M
- 1-year return
- +527.9%
- Typical daily move
- ±5.6%
- Typical 20-day move
- ±14.7%
- 50-day average
- $12.44
- 200-day average
- $8.05
- Next earnings
- Nov 11
- Shares outstanding
- 201.9M
SELLAS Life Sciences swing-trade checklist
SELLAS Life Sciences scores 2 supportive, 3 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive3 mixed0 headwinds
- Trendmixed
Averages disagree
Close $11.93 sits between the 50-day ($12.44) and 200-day ($8.05) averages, or the averages disagree.
See the chart - GekkoIndexmixed
58.5, Neutral
Reading 58.5 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
32.2% below
Price is 32.2% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 30 days
Next report Nov 11, 2026, 30 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
+28.2% on average
From this point in the calendar, the next 20 trading days averaged +28.2% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
SELLAS Life Sciences stock chart and price history
SELLAS Life Sciences closed at $11.93 on Oct 12, 2026, +527.9% over the past year, inside a 52-week range of $1.39 to $15.88.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +3.3%
- 3 months
- −10.9%
- 6 months
- +150.6%
- 1 year
- +527.9%
The full SLS chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open SLS in Gekko
Follow SELLAS Life Sciences through every session
Put SLS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track SLS in GekkoFree for 7 days. No credit card required.
About SELLAS Life Sciences
SELLAS Life Sciences is a clinical-stage biopharmaceutical company working on treatments for cancer in the United States, with its programs still in late-stage development rather than on the market. Its main candidates are galinpepimut-S, an immunotherapy built around a peptide that targets the Wilms tumor 1 antigen, and SLS009, also called tambiciclib, a small molecule designed to inhibit CDK9. The company is best known for advancing these two therapies through clinical trials aimed at a range of cancer types.
Much of its work is carried out through partnerships rather than alone. It collaborates with Merck to test galinpepimut-S alongside the PD1 blocker pembrolizumab in a trial covering several blood and solid tumor cancers, works with GenFleet Therapeutics in Shanghai on the compound GFH009, and has an arrangement with Memorial Sloan Kettering Cancer Center to develop and bring to market a WT1 peptide vaccine technology originated there.
SELLAS Life Sciences is headquartered in New York, New York. Its shares are listed on the NASDAQ under the ticker SLS.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- sellaslifesciences.com
SELLAS Life Sciences GekkoIndex: the smart money zone
SELLAS Life Sciences’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 58.5, in the Neutral zone, down 1.8 points over five sessions.
58.5Neutral
Down 1.8 points over five sessions, from the Accumulation zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 16 | Not available | |||
| Accumulation | 177 | +3.9% | +21.9% | ||
| Neutral (current zone) | 412 | +2.4% | +8.9% | ||
| Distribution | 72 | +6.0% | +15.0% | ||
| Selling | 5 | Too few readings yet | |||
Average SLS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the SLS price, zone by zone.Track SLS in Gekko
Is SELLAS Life Sciences stock overvalued? Gekko Fair Value
SELLAS Life Sciences trades 32.2% below Gekko Fair Value of $17.59, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what SELLAS Life Sciences shares are worth, recalculated every trading day.
$17.59
Gekko Fair Value, Oct 10, 2026
32.2% Undervalued
At the end of Aug 2026 the price was 47.6% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open SLS in Gekko
SELLAS Life Sciences insider and Congress trading
No open-market insider purchases were filed for SELLAS Life Sciences, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in SLS were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for SLS, plotted on the chart in Gekko.Open SLS in Gekko
SELLAS Life Sciences earnings: next date and track record
SELLAS Life Sciences reports on Nov 11, 2026 (30 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Nov 11, 2026
30 days away
- EPS estimate
- −$0.05
7 of 8reports beat the EPS estimate
±5.9%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 11, 2026 | −$0.05 est −$0.04 | — | +6.6% |
| May 12, 2026 | −$0.05 est −$0.07 | — | +24.4% |
| Mar 19, 2026 | −$0.05 est −$0.06 | — | −3.8% |
| Nov 12, 2025 | −$0.06 est −$0.06 | — | −3.3% |
| Aug 12, 2025 | −$0.07 est −$0.08 | — | +0.6% |
| May 13, 2025 | −$0.07 est −$0.21 | — | −1.9% |
| Mar 20, 2025 | −$0.08 est −$0.11 | — | −0.8% |
| Nov 13, 2024 | −$0.10 est −$0.13 | — | −5.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
SELLAS Life Sciences stock forecast and analyst price targets
Analysts’ average 12-month price target for SELLAS Life Sciences is $32.50, +172.4% from the last close.
$32.50consensus 12-month target, +172.4% from the last close
+8.9%average 20-day move after past Neutral readings
+28.2%average move over the next 20 trading days in the last 5 years
±5.6%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
SELLAS Life Sciences seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, SELLAS Life Sciences averaged +28.2% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.7% | 4 of 5 |
| Next 10 trading days | +3.9% | 3 of 5 |
| Next 15 trading days | +23.7% | 2 of 5 |
| Next 20 trading days | +28.2% | 2 of 5 |
| Next 30 trading days | −6.5% | 2 of 5 |
For scale, SLS’s typical 20-trading-day move in either direction is about 14.7%.
SELLAS Life Sciences market cap and key statistics
SELLAS Life Sciences’s market cap is $2.22B and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $2.22B
- EPS, TTM
- −$0.21
- Gekko Fair Value
- $17.59
Trading
- Volume
- 4.02M
- Avg volume, 20 days
- 5.18M
- 52-week high
- $15.88
- 52-week low
- $1.39
- Shares outstanding
- 201.9M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -39.6%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 2.57
- Typical daily move
- ±5.6%
- Typical 20-day move
- ±14.7%
SELLAS Life Sciences stock news this week
Coverage of SELLAS Life Sciences this week reads neutral: 0 positive, 2 neutral and 1 negative headlines.
- SELLAS Life Sciences Group, Inc. (SLS) options chainYahoo Finance Australia, Oct 7
- SELLAS Life Sciences Group, Inc. (RXK3.F) stock price, news, quote and historyYahoo Finance UK, Oct 7
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLSFinancialContent, Oct 6
SELLAS Life Sciences peers
SELLAS Life Sciences’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
SELLAS Life Sciences stock FAQ
What is SELLAS Life Sciences’s market cap?
SELLAS Life Sciences’s market cap is $2.22B at the Oct 12, 2026 close of $11.93, with 201.9M shares outstanding.
What is the SELLAS Life Sciences stock forecast?
The consensus analyst 12-month price target for SELLAS Life Sciences is $32.50, +172.4% from the last close. Gekko doesn’t publish price predictions of its own.
Is SELLAS Life Sciences stock overvalued or undervalued?
On Gekko’s estimate SELLAS Life Sciences is undervalued: the Oct 12, 2026 close of $11.93 is 32.2% below Gekko Fair Value of $17.59. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does SELLAS Life Sciences report earnings next?
SELLAS Life Sciences is expected to report on Nov 11, 2026 (30 days away). Analysts expect earnings of −$0.05 per share. SELLAS Life Sciences beat the earnings estimate in 7 of its last 8 reports, moving 5.9% on average across the report.
What is SELLAS Life Sciences’s 52-week high and low?
SELLAS Life Sciences’s 52-week high is $15.88 and its 52-week low is $1.39; it closed at $11.93 on Oct 12, 2026, +527.9% over the past year.
Is SELLAS Life Sciences stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (fair value and earnings risk), 3 as mixed (trend, gekkoindex and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See SELLAS Life Sciences the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.